TransMedics Group, Inc. $TMDX Position Increased by Wellington Management Group LLP

Key Points

• Wellington Management increased its TransMedics position by 6.1% in the second quarter, adding 29,500 shares for a total of 515,973 shares valued at approximately $34.3 million. Institutional investors collectively own 99.67% of the company.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings per share of $0.44 missed the $0.50 consensus forecast. Shares opened at $89.98, with a market capitalization of about $3.11 billion.
• Analysts maintain a consensus “Hold” rating with an average price target of $124.18, although several firms recently lowered targets. A company director also sold shares worth $722,377 to cover tax withholding obligations related to vested equity awards.

Wellington Management Group LLP grew its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 6.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 515,973 shares of the company's stock after buying an additional 29,500 shares during the quarter. Wellington Management Group LLP owned approximately 1.49% of TransMedics Group worth $34,271,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Harvest Fund Management Co. Ltd purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $29,000. Allworth Financial LP raised its stake in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company's stock valued at $30,000 after purchasing an additional 113 shares during the period. Parallel Advisors LLC lifted its holdings in shares of TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company's stock valued at $34,000 after purchasing an additional 83 shares in the last quarter. Ascentis Independent Advisors acquired a new stake in shares of TransMedics Group in the first quarter worth $30,000. Finally, North Star Investment Management Corp. acquired a new stake in shares of TransMedics Group in the first quarter worth $30,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $89.98 on Friday. The firm has a market cap of $3.11 billion, a price-to-earnings ratio of 23.13 and a beta of 1.90. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The business has a fifty day simple moving average of $80.14 and a 200 day simple moving average of $92.21.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million during the quarter, compared to analysts' expectations of $184.00 million. During the same quarter last year, the firm earned $0.92 EPS. The business's revenue for the quarter was up 20.7% compared to the same quarter last year. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TMDX has been the topic of several recent analyst reports. Piper Sandler reissued an "overweight" rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Weiss Ratings upgraded TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday. UBS Group lowered their target price on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 5th. Stifel Nicolaus increased their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a "hold" rating in a research report on Thursday, June 18th. Finally, Zacks Research lowered shares of TransMedics Group from a "hold" rating to a "strong sell" rating in a research report on Monday, July 6th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $124.18.

Insider Activity at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company's stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company's stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source